January 9, 2018 / 11:56 PM / a month ago

BRIEF-Tax reform relatively neutral for Mylan-CFO

Jan 9 (Reuters) - Mylan:

* SAYS ITS BIOSIMILAR FOR AMGEN‘S NEULASTA COULD BE A “MID-YEAR OPPORTUNITY”

* SAYS U.S. TAX REFORM RELATIVELY NEUTRAL FOR THE COMPANY Source text for Eikon: Further company coverage: (Reporting By Michael Erman)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below